News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
194,844 Results
Type
Article (18592)
Company Profile (130)
Press Release (176109)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (59023)
Career Advice (957)
Deals (9552)
Drug Delivery (45)
Drug Development (23821)
Employer Resources (73)
FDA (2535)
Job Trends (4358)
News (93730)
Policy (5928)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (493)
Accelerated approval (15)
Adcomms (16)
Allergies (41)
Alliances (16413)
ALS (76)
Alzheimer's disease (598)
Antibody-drug conjugate (ADC) (189)
Approvals (2521)
Artificial intelligence (223)
Autoimmune disease (88)
Automation (14)
Bankruptcy (83)
Best Places to Work (2925)
BIOSECURE Act (20)
Biosimilars (64)
Biotechnology (117)
Bladder cancer (73)
Brain cancer (28)
Breast cancer (236)
Cancer (2020)
Cardiovascular disease (142)
Career advice (790)
Career pathing (24)
CAR-T (186)
CDC (5)
Cell therapy (478)
Cervical cancer (16)
Clinical research (20540)
Collaboration (927)
Company closure (3)
Compensation (290)
Complete response letters (33)
COVID-19 (781)
CRISPR (46)
C-suite (513)
Cystic fibrosis (63)
Data (2468)
Denatured (13)
Depression (47)
Diabetes (134)
Diagnostics (1168)
Digital health (6)
Diversity (3)
Diversity, equity & inclusion (21)
Drug discovery (145)
Drug pricing (49)
Drug shortages (2)
Duchenne muscular dystrophy (112)
Earnings (17247)
Editorial (29)
Employer branding (8)
Employer resources (73)
Events (33788)
Executive appointments (541)
FDA (3462)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (3)
Frontotemporal dementia (17)
Funding (760)
Gene editing (110)
Generative AI (25)
Gene therapy (374)
GLP-1 (390)
Government (728)
Grass and pollen (1)
Guidances (89)
Healthcare (2455)
HIV (12)
Huntington's disease (33)
IgA nephropathy (53)
Immunology and inflammation (177)
Immuno-oncology (38)
Indications (32)
Infectious disease (891)
Inflammatory bowel disease (105)
Inflation Reduction Act (3)
Influenza (46)
Intellectual property (104)
Interviews (142)
IPO (4201)
IRA (14)
Job creations (1485)
Job search strategy (707)
JPM (43)
Kidney cancer (7)
Labor market (59)
Layoffs (246)
Leadership (26)
Legal (1219)
Liver cancer (24)
Longevity (6)
Lung cancer (226)
Lymphoma (184)
Machine learning (25)
Management (24)
Manufacturing (400)
MASH (54)
Medical device (798)
Medtech (801)
Mergers & acquisitions (5795)
Metabolic disorders (476)
Multiple sclerosis (71)
NASH (8)
Neurodegenerative disease (173)
Neuropsychiatric disorders (42)
Neuroscience (1146)
Neurotech (1)
NextGen: Class of 2026 (1472)
Non-profit (487)
Now hiring (39)
Obesity (262)
Opinion (199)
Ovarian cancer (78)
Pain (63)
Pancreatic cancer (96)
Parkinson's disease (130)
Partnered (16)
Patents (184)
Patient recruitment (192)
Peanut (18)
People (23250)
Pharmaceutical (16)
Phase 1 (7916)
Phase 2 (9787)
Phase 3 (5526)
Pipeline (1980)
Policy (129)
Postmarket research (313)
Preclinical (3258)
Press Release (61)
Prostate cancer (72)
Psychedelics (30)
Radiopharmaceuticals (97)
Rare diseases (411)
Real estate (2485)
Recruiting (40)
Regulatory (5388)
Reports (23)
Research institute (541)
Resumes & cover letters (154)
Rett syndrome (11)
RNA editing (17)
RSV (26)
Schizophrenia (37)
Series A (162)
Series B (108)
Service/supplier (5)
Sickle cell disease (40)
Special edition (16)
Spinal muscular atrophy (55)
Sponsored (16)
Startups (1825)
State (1)
Stomach cancer (7)
Supply chain (33)
Tariffs (37)
The Weekly (52)
Vaccines (347)
Venture capital (82)
Weight loss (159)
Women's health (21)
Worklife (9)
Date
Today (41)
Last 7 days (227)
Last 30 days (836)
Last 365 days (11902)
2026 (1223)
2025 (11963)
2024 (12718)
2023 (13269)
2022 (16165)
2021 (17027)
2020 (13312)
2019 (9589)
2018 (7626)
2017 (9039)
2016 (8174)
2015 (9480)
2014 (9802)
2013 (9513)
2012 (6147)
2011 (6492)
2010 (5869)
Location
Africa (340)
Alabama (54)
Alaska (3)
Arizona (72)
Arkansas (2)
Asia (14343)
Australia (2898)
California (4328)
Canada (1210)
China (488)
Colorado (94)
Connecticut (162)
Delaware (104)
Europe (32015)
Florida (524)
Georgia (76)
Hawaii (2)
Idaho (14)
Illinois (211)
India (30)
Indiana (221)
Iowa (7)
Japan (177)
Kansas (24)
Kentucky (6)
Louisiana (6)
Maine (2)
Maryland (552)
Massachusetts (3389)
Michigan (112)
Minnesota (199)
Mississippi (1)
Missouri (34)
Montana (10)
Nebraska (5)
Nevada (35)
New Hampshire (9)
New Jersey (974)
New Mexico (11)
New York (1003)
North Carolina (606)
North Dakota (6)
Northern California (2081)
Ohio (99)
Oklahoma (10)
Oregon (11)
Pennsylvania (810)
Puerto Rico (8)
Rhode Island (17)
South America (408)
South Carolina (7)
Southern California (1717)
Tennessee (28)
Texas (583)
United States (14318)
Utah (64)
Virginia (39)
Washington D.C. (25)
Washington State (539)
West Virginia (1)
Wisconsin (33)
194,844 Results for "viva biotech".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Viva Biotech’s invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
December 15, 2025
·
5 min read
Press Releases
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech’s Discovery Insights
September 2, 2025
·
4 min read
Insights
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
January 29, 2026
·
3 min read
·
Jennifer Smith-Parker
Insights
Uptick in Dealmaking, Chinese Partnerships Drive Biotech’s Comeback
Biotech’s slump may finally be over in 2026. In interviews with
BioSpace
, Zymeworks’ CEO Ken Galbraith and Zai Lab’s President and COO Josh Smiley explain what’s fueling the comeback.
December 17, 2025
·
3 min read
·
Jennifer Smith-Parker
Opinion
Trump Must Make Biotech Innovation a National Priority
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
January 14, 2026
·
7 min read
·
Cyriac Roeding
IPO
2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?
Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors.
February 4, 2026
·
11 min read
·
Tristan Manalac
Press Releases
AVS Schedule of Events Announced for TCT and VIVA Meetings
October 23, 2025
·
2 min read
Deals
With Biotech Back, Analysts Make Their Picks for 2026
The second half finished strong after two tumultuous years. What will 2026 bring for the biotech sector?
December 22, 2025
·
2 min read
·
Annalee Armstrong
Mergers & acquisitions
At JPM26, Policy and Politics Will Loom Large for Pharma as Biotech Sees the Sun
Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a break after a few tough years.
January 9, 2026
·
4 min read
·
Annalee Armstrong
Rare diseases
Rare Disease Biotechs Stand To Lose $4B if Priority Voucher Program Not Reinstated: Report
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
January 26, 2026
·
7 min read
·
Heather McKenzie
1 of 19,485
Next
